Results 151 to 160 of about 45,614 (245)

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

Algorithms in Allergy: Hereditary Angioedema

open access: yes
Allergy, EarlyView.
Konrad Bork   +3 more
wiley   +1 more source

Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials.

open access: yesJAMA Dermatol
Casale TB   +12 more
europepmc   +1 more source

Early Detection of Lower Adherence to Long‐Term e‐Diary Recording: A Checkpoint to Target Early Educational Intervention in Seasonal Allergic Rhinitis?

open access: yesClinical &Experimental Allergy, EarlyView.
Adherence to e‐Diary reporting was investigated in a blended care setting among pollen allergic patients with heterogeneous cultural backgrounds. A stable ‘higher’ and a more variable ‘lower’ adherence cluster were identified. Early identification of lower adherence is possible and might inform early interventions to improve patient adherence. ABSTRACT
S. Dramburg   +55 more
wiley   +1 more source

Treatment response in chronic urticaria: analysis of clinical and laboratory predictors. [PDF]

open access: yesAn Bras Dermatol
Fonseca JTD   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy